Learn More
The authors are members of the ISPD Ad Hoc Advisory Committee on Peritoneal Dialysis Related Infections. P eritonitis remains a leading complication of perito-neal dialysis (PD). Around 18% of the infection-related mortality in PD patients is the result of peritonitis. Although less than 4% of peritonitis episodes result in death, peritonitis is a "(More)
T his current version provides a summary of recommendations for best practice in creating peritoneal access for patients on peritoneal dialysis (PD). A more detailed review of peritoneal access is available in the report from the Renal Association Working Party on Peritoneal Access (final version April 2008) available at www.renal.org. These guidelines are(More)
Oestrous behaviour and occurrence of ovulation was studied in 13 jenny asses (3-18 years) during a 15-month period. Teasing was performed daily and follicular growth, ovulation and changes of the genitalia were checked every other day by rectal palpation during dioestrus or the anovulatory season or daily during oestrus and when a follicle greater than or(More)
OBJECTIVE To survey nurses around the world about current practices for peritoneal dialysis (PD) home training programs. DESIGN Random sampling of nurses to complete a written survey from the International Society for Peritoneal Dialysis Nursing Liaison Committee. SETTINGS United States, Canada, South America (Brazil, Columbia), The Netherlands, Hong(More)
Being aware of controversies and lack of evidence in peritoneal dialysis (PD) training, the Nursing Liaison Committee of the International Society for Peritoneal Dialysis (ISPD) has undertaken a review of PD training programs around the world in order to develop a syllabus for PD training. This syllabus has been developed to help PD nurses train patients(More)
We performed a phase II trial to test whether a cyclooxygenase (COX-2) inhibitor, celecoxib, added to standard first-line combination chemotherapy (CT) and as maintenance therapy would improve outcomes in extensive-stage (ES) small-cell lung cancer (SCLC). This was a multicenter trial in CT-naive patients with ES-SCLC. They received standard cisplatin and(More)